Showing 2111-2120 of 5697 results for "".
- FDA Issues Draft Guidance to Accelerate Development of Gene Therapies Using Existing Scientific Knowledgehttps://modernod.com/news/fda-issues-draft-guidance-to-accelerate-development-of-gene-therapies-using-existing-scientific-knowledge/2487384/The FDA released draft guidance aimed at helping developers bring promising gene th
- Tarsus Partners With John Cena on Demodex Blepharitis Awareness Campaignhttps://modernod.com/news/tarsus-partners-with-john-cena-on-demodex-blepharitis-awareness-campaign/2487094/Tarsus Pharmaceuticals is partnering with celebrity John Cena on a campaign to raise awareness of Demodex blepharitis. As part of this campaign, Cena will detail his own experience with Demodex blepharitis and lotilaner ophthalmic solution 0.25% (Xdemvy) the first FDA-approved t
- SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurityhttps://modernod.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486398/Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a
- Study Links Vitamin D Deficiency to Higher Risk of Dry Eye Diseasehttps://modernod.com/news/study-links-vitamin-d-deficiency-to-higher-risk-of-dry-eye-disease/2486076/Key Takeaways A large retrospective cohort study found that adults with vitamin D deficiency had a significantly higher risk of developing dry eye
- Antigua and Barbuda to Host First Global Summit for Eye Health in November 2026https://modernod.com/news/antigua-and-barbuda-to-host-first-global-summit-for-eye-health-in-november-2026/2485941/Key Takeaways Antigua and Barbuda will host the first-ever Global Summit for Eye Health on November 2, 2026, bringin
- Nordic Pharma Announces European Launch of Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-announces-european-launch-of-lacrifill-canalicular-gel/2485691/Nordic Group, the parent company of Nordic Pharma, announced the European launch of Lacrifill, a novel therapy for the management of dry eye disease. Following CE mark approval in April 2025, Lacrifill is now available to healthcare professionals and patients acros
- Centre for Sight Launches 'Eye Health MOT' to Support Early Detection and Long-Term Vision Carehttps://modernod.com/news/centre-for-sight-launches-eye-health-mot-to-support-early-detection-and-long-term-vision-care/2485486/Centre for Sight has launched a new 'Eye Health MOT' service for people aged 40 and over, designed to offer a comprehensive, consultant-led assessment to detect early signs of eye disease before symptoms appear. According to C
- WAVE Eye Care Announces New Integration Between Topcon MYAH and WAVE Lens Designer Softwarehttps://modernod.com/news/wave-eye-care-announces-new-integration-between-topcon-myah-and-wave-lens-designer-software/2485329/At the Global Specialty Lens Symposium (GSLS) in Las Vegas, WAVE Eye Care announced a integration between the Topcon MYAH and WAVE Lens Designer Software designed to streamline the specialty contact lens fitting and design process for eye care practitioners.
- Nanodropper Now Operating as Mu Medical Under New Consolidation Planhttps://modernod.com/news/nanodropper-now-operating-as-mu-medical-under-new-consolidation-plan/2485284/Nanodropper, provider of micro-volume ophthalmic delivery technology, announced that Bedo Solutions and Viseon Labs have agreed on terms to join its eyecare platform under a new corporate identity, Mu Medical. Financial terms of the deal were not disclosed.
- Celularity Enters Strategic Partnership with DefEYE to Advance Regenerative Therapies in Eye Carehttps://modernod.com/news/celularity-enters-strategic-partnership-with-defeye-to-advance-regenerative-therapies-in-eye-care/2484300/Celularity announced a strategic partnership with DefEYE, a newly established ophthalmic product and technology company. Under the terms of the agreement, Celularity has executed an exclusive license and pricing arrangement with DefEYE, following Celularity&rs